AbCheck discovers and optimizes human antibodies leveraging several proprietary platforms including in vitro and in vivo technologies.
We use phage/yeast display libraries (AbSieve), mass humanization, and antibody optimization (AbAccel) to provide high quality leads. Our technology platform can be used in conjunction with all antibody designs and allows selection of optimized leads from a huge number of variants. Flexibly adapting to our partner’s needs, we offer a variety of business models, including deals without royalties. AbCheck has proven its capabilities in multiple partnerships throughout the US and Europe. AbCheck is a wholly owned subsidiary of Affimed GmbH.